欧盟HMA药品数据库(European Union HMA Authorisation of Medicines DataBase)
MR编号DE/V/0159/001
药品名称Spasmium compositum
活性成分
    • hyoscine butylbromide 4.0 mg/ml
    • metamizole sodium monohydrate 500.0 mg/ml
剂型Solution for injection
上市许可持有人Richter Pharma AG
参考成员国 - 产品名称Germany (DE)
Spasmium compositum
互认成员国 - 产品名称
    • Denmark (DK)
    • Iceland (IS)
      Spasmium vet. 500 mg/ml + 4 mg ml Stungulyf, lausn handa hestum, nautgripum, svínum og hundum
    • United Kingdom (Northern Ireland) (XI)
    • Ireland (IE)
      Spasmium Compositum 500.0mg/ml/4.0mg/ml Solution for Injection
    • Austria (AT)
      Spasmium comp. 500 mg/ml + 4 mg/ml Injektionslösung für Tiere
    • Spain (ES)
    • Portugal (PT)
    • Italy (IT)
    • Greece (GR)
    • Sweden (SE)
    • Norway (NO)
      Spasmium vet
    • Finland (FI)
    • Poland (PL)
    • Latvia (LV)
      Spasmium comp. 500 mg/ml + 4 mg/ml
    • Lithuania (LT)
    • Estonia (EE)
      Spasmium comp.
    • Hungary (HU)
    • Bulgaria (BG)
    • Czechia (CZ)
    • Romania (RO)
    • Slovakia (SK)
    • Slovenia (SI)
    • Croatia (HR)
许可日期2015/06/17
最近更新日期2024/07/26
药物ATC编码
    • QA03BB01 butylscopolamine
申请类型
  • TypeLevel1:[not specified]
  • TypeLevel2:[not specified]
  • TypeLevel3:Generic - art 13.2 Dir 2001/82/EC
  • TypeLevel4:[not specified]
  • TypeLevel5:[not specified]
附件文件下载
市场状态Positive
©2006-2025 Drugfuture->European Union HMA Authorisation of Medicines DataBase